OptiNose Inc. (OPTN)
6.04
0.09 (1.51%)
At close: Feb 20, 2025, 3:59 PM
6.00
-0.66%
After-hours: Feb 20, 2025, 03:59 PM EST
undefined% (undefined)
| Bid | 5.76 |
| Market Cap | 60.73M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -4.35 |
| PE Ratio (ttm) | -1.39 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 6.48 |
| Volume | 17,753 |
| Avg. Volume (20D) | 50,886 |
| Open | 6.01 |
| Previous Close | 5.95 |
| Day's Range | 6.01 - 6.49 |
| 52-Week Range | 4.82 - 31.50 |
| Beta | undefined |
About OPTN
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb c...
Sector Healthcare
IPO Date Oct 13, 2017
Employees 132
Stock Exchange NASDAQ
Ticker Symbol OPTN
Website https://www.optinose.com
Analyst Forecast
According to 3 analyst ratings, the average rating for OPTN stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 181.46% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
OptiNose Inc. is scheduled to release its earnings on Mar 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
-21.88%
OptiNose shares are trading lower after the compan...
Unlock content with
Pro Subscription
9 months ago
+7.69%
OptiNose shares are trading higher after the company announced it expects its FY24 net product revenue to be between $85 million and $95 million. The company announced a $55 million registered direct offering.
